National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
NCI Drug Dictionary
Page Options
Print This Page
More NCI Dictionaries
Dictionary of Cancer Terms

Glossary of Statistical Terms

NCI Dictionary of Genetics Terms

Terminology Resources
Quit Smoking Today
Search for
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

human monoclonal antibody 216
A naturally-occurring human IgM monoclonal antibody with potential antineoplastic activity. Human monoclonal antibody 216, derived from the gene VH4-34, binds to the glycosylated epitope CDIM on the surface of both malignant and normal B cells. Upon binding to B cells, this antibody may crosslink two or more CDIM molecules, resulting in the formation of cell membrane pores, the disruption of cell membrane integrity, and B cell lysis; this mechanism of antibody-mediated cell death is direct and does not involve mechanisms of complement-mediated cytotoxicity or antibody-depndent cell-mediated cytotoxicity (ADCC). CDIM is the glyco-moiety of a 75 kD MW B-cell cell surface glycoprotein. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Abbreviation:MoAb 216



Previous:huBC1-huIL12 fusion protein AS1409, HuC242-DM4, human anti-alpha-v integrin monoclonal antibody, human anti-TGF-beta monoclonal antibody GC1008, human gp100 plasmid DNA vaccine
Next:human monoclonal antibody B11-hCG beta fusion protein CDX-1307, human papillomavirus 16/18 L1 virus-like particle/AS04 vaccine, human prostate-specific membrane antigen plasmid DNA vaccine, HuMax-CD38, Hycamtin

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov